Area:
Limbic system, serotonin
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, David J. Mokler is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 1985 — 1986 |
Mokler, David J |
F32Activity Code Description:
To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
5-Hydroxtrytamine Sites of Hallucinogen Drug Action @ Virginia Commonwealth University |
0.936 |
| 1991 — 1992 |
Mokler, David J |
R03Activity Code Description:
To provide research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies which are generally for preliminary short-term projects and are non-renewable. |
5 Hydroxtryptamine Mechanisms of Hallucinogenic Drugs @ University of New England
Hallucinogenic drugs such as lysergic acid diethylamide (LSD) and (plus/minus)-3,4-methylene-dioxymethamphetamine (MDMA) are abused in our society. The hallucinogenic indole-alkylamines LSD and 5-methoxy-N, N- dimethyltryptamine (5-MeODMT), and the phenalkylamines MDMA and (plus/minus)-2,5-dimethoxy-4-methylamphetamine (DOM) interact with the 5- hydroxytryptamine (5-HT) neuronal systems of the brain. The interactions of these drugs with 5-HT systems have been under investigation for over 20 years and have provided new opportunities for advancing our understanding of the actions of the hallucinogens. The method of in vivo microdialysis for simultaneous measurement of the extracellular levels of 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in discrete areas of the forebrain will allow us to determine the effects of hallucinogenic drugs on 5-HT neurons activated by electrical stimulation of the dorsal and median raphe nuclei. Microdialysis probes will be implanted into medial prefrontal cortex, striatum, nucleus accumbens, hippocampus and habenular nuclei. These forebrain sites are primary areas of termination for 5-HT neuronal pathways originating in the midbrain raphe. Behavioral discrimination will be used to provide behavioral data to correlate with neurochemical data. Animals will be trained to discriminate electrical stimulation of the dorsal or median raphe nucleus from non-stimulation. Agonists and antagonists at subtypes of 5-HT receptors will be examined for their effects on behavioral discrimination as well as brain neurochemistry following electrical stimulation of the raphe nuclei. The effects of LSD, 5-MeODMT, DOM and MDMA will be examined in these paradigms to determine the differential roles of the raphe nuclei and subtypes of 5-HT receptors in the actions of these drugs. Changes in the release of 5-HT in brain areas will be correlated with the results of behavioral experiments. These studies will develop the experimental basis to examine the neurochemical and behavioral actions of hallucinogens on both electrical and drug-induced activation of the major forebrain 5-HT nuclei, the dorsal and median raphe. These studies will also allow important insight into the functional nature of the 5-hydroxytryptamine neuronal pathways in conscious animals and will lead to a better understanding of the mechanisms and sites of action of these hallucinogenic drugs of abuse.
|
1 |